Effects of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on Inflammatory Mediators

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the study is to evaluate the effect of vaginal lactoferrin administration on amniotic fluid PGE2 level and MMP-TIMP system in women undergoing genetic amniocentesis. Two groups of patients will be prospectively enrolled: not treated with lactoferrin and treated with vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Università degli Studi di Ferrara
• Treatments: Lactoferrin

Criteria

Inclusion Criteria:

• singleton gestation

• maternal age as indication to fetal karyotyping

Exclusion Criteria:

• consumption of drugs interfering with the immune system

• previous miscarriages

• pregnancy at risk for maternal or fetal disease

• lactose intolerance